Stock Track | Arrowhead Pharmaceuticals Soars 5.49% Intraday on Morgan Stanley Price Target Hike and Bullish Analyst Sentiment

Stock Track

Nov 26

Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.

The rally was fueled by Morgan Stanley raising its price target on Arrowhead to $48 from $45, while maintaining an Equal Weight rating. Additionally, TD Cowen reiterated its Buy rating, citing promising developments in the Redemplo launch and strategic advancements in obesity treatments. These analyst actions underscore the market's optimism about Arrowhead's future performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1128969858"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128969858\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128969858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128969858","market":"nz","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 5.49% Intraday on Morgan Stanley Price Target Hike and Bullish Analyst Sentiment","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.</p><p>The rally was fueled by Morgan Stanley raising its price target on Arrowhead to $48 from $45, while maintaining an Equal Weight rating. Additionally, TD Cowen reiterated its Buy rating, citing promising developments in the Redemplo launch and strategic advancements in obesity treatments. These analyst actions underscore the market's optimism about Arrowhead's future performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 5.49% Intraday on Morgan Stanley Price Target Hike and Bullish Analyst Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 5.49% Intraday on Morgan Stanley Price Target Hike and Bullish Analyst Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-26 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.</p><p>The rally was fueled by Morgan Stanley raising its price target on Arrowhead to $48 from $45, while maintaining an Equal Weight rating. Additionally, TD Cowen reiterated its Buy rating, citing promising developments in the Redemplo launch and strategic advancements in obesity treatments. These analyst actions underscore the market's optimism about Arrowhead's future performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1128969858","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128969858","pubTimestamp":1764167901,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.The rally was fueled by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|Arrowhead Pharmaceuticals盘中大涨5.49%，因摩根士丹利上调目标价及分析师情绪看涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.The rally was fueled by Morgan Stanley raising its price target on Arrowhead to $48 from $45, while maintaining an Equal Weight rating. Additionally, TD Cowen reiterated its Buy rating, citing promising developments in the Redemplo launch and strategic advancements in obesity treatments. These analyst actions underscore the market's optimism about Arrowhead's future performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}